Top

Published in:

01-04-2018

Practical advantages of contrast-enhanced ultrasound in abdominopelvic radiology

Authors: Praveen Ganti Ranganath, Michelle L. Robbin, Susan J. Back, Edward G. Grant, David T. Fetzer

Published in: Abdominal Radiology | Issue 4/2018

Abstract

Computed tomography (CT) and magnetic resonance imaging (MRI) are two of the workhorse modalities of abdominopelvic radiology. However, these modalities are not without patient- and technique-specific limitations that may prevent a timely and accurate diagnosis. Contrast-enhanced ultrasound (CEUS) is an effective, rapid, and cost-effective imaging modality with expanding clinical utility in the United States. In this pictorial essay, we provide a case-based discussion demonstrating the practical advantages of CEUS in evaluating a variety of pathologies in which CT or MRI was precluded or insufficient. Through these advantages, CEUS can serve a complementary role with CT and MRI in comprehensive abdominopelvic radiology.

Available only for authorised users

Mattrey RF, Scheible FW, Gosink BB, et al. (1982) Perfluoroctylbromide: a liver/spleen-specific and tumor-imaging ultrasound contrast material. Radiology 145(3):759–762. https://doi.org/10.1148/radiology.145.3.7146409 CrossRefPubMed

Mattrey RF, Strich G, Shelton RE, et al. (1987) Perfluorochemicals as US contrast agents for tumor imaging and hepatosplenography: preliminary clinical results. Radiology 163(2):339–343. https://doi.org/10.1148/radiology.163.2.3550878 CrossRefPubMed

First Approval by U.S. Food and Drug Administration for Contrast Enhanced Ultrasonography of the Liver Received by Bracco Diagnostics Inc. for LUMASON^® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use (2016). Bracco Diagnostics Inc., Monroe Township

ACR Committee on Drugs and Contrast Media (2016) ACR manual on contrast media v10.2. ACR website. https://www.acr.org/Clinical-Resources/Contrast-Manual. Accessed 20 Sep 2017

Benozzi L, Cappelli G, Granito M, et al. (2009) Contrast-enhanced sonography in early kidney graft dysfunction. Transplant Proc 41(4):1214–1215. https://doi.org/10.1016/j.transproceed.2009.03.029 CrossRefPubMed

Lemy AA, del Marmol V, Kolivras A, et al. (2010) Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience. J Am Acad Dermatol 63(3):389–399. https://doi.org/10.1016/j.jaad.2009.10.038 CrossRefPubMed

Abbas FM, Julie BM, Sharma A, Halawa A (2016) “Contrast nephropathy” in renal transplantation: is it real? World J Transplant 6(4):682–688. https://doi.org/10.5500/wjt.v6.i4.682 CrossRefPubMedPubMedCentral

Cheungpasitporn W, Thongprayoon C, Mao MA, et al. (2017) Contrast-induced acute kidney injury in kidney transplant recipients: a systematic review and meta-analysis. World J Transplant 7(1):81–87. https://doi.org/10.5500/wjt.v7.i1.81 CrossRefPubMedPubMedCentral

Haider M, Yessayan L, Venkat KK, et al. (2015) Incidence of contrast-induced nephropathy in kidney transplant recipients. Transplant Proc 47(2):379–383. https://doi.org/10.1016/j.transproceed.2015.01.008 CrossRefPubMed

10.

Jin Y, Yang C, Wu S, et al. (2015) A novel simple noninvasive index to predict renal transplant acute rejection by contrast-enhanced ultrasonography. Transplantation 99(3):636–641. https://doi.org/10.1097/TP.0000000000000382 CrossRefPubMed

11.

Wang X, Yu Z, Guo R, Yin H, Hu X (2015) Assessment of postoperative perfusion with contrast-enhanced ultrasonography in kidney transplantation. Int J Clin Exp Med 8(10):18399–18405PubMedPubMedCentral

12.

Harvey CJ, Alsafi A, Kuzmich S, et al. (2015) Role of US contrast agents in the assessment of indeterminate solid and cystic lesions in native and transplant kidneys. Radiographics 35(5):1419–1430. https://doi.org/10.1148/rg.2015140222 CrossRefPubMed

13.

McCarville MB, Kaste SC, Hoffer FA, et al. (2012) Contrast-enhanced sonography of malignant pediatric abdominal and pelvic solid tumors: preliminary safety and feasibility data. Pediatr Radiol 42(7):824–833. https://doi.org/10.1007/s00247-011-2338-2 CrossRefPubMedPubMedCentral

14.

Piscaglia F, Bolondi L, Italian Society for Ultrasound in M, Biology Study Group on Ultrasound Contrast A (2006) The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol 32(9):1369–1375. https://doi.org/10.1016/j.ultrasmedbio.2006.05.031 CrossRefPubMed

15.

Yusuf GT, Sellars ME, Deganello A, Cosgrove DO, Sidhu PS (2017) Retrospective analysis of the safety and cost implications of pediatric contrast-enhanced ultrasound at a single center. AJR Am J Roentgenol 208(2):446–452. https://doi.org/10.2214/AJR.16.16700 CrossRefPubMed

16.

Bracco Diagnostics Inc. (2016) Lumason prescribing information. Lumason website. https://imaging.bracco.com/us-en/lumason. Accessed 20 Sep 2017

17.

Sawhney S, Wilson SR (2017) Can ultrasound with contrast enhancement replace nonenhanced computed tomography scans in patients with contraindication to computed tomography contrast agents? Ultrasound Q 33(2):125–132. https://doi.org/10.1097/RUQ.0000000000000271 CrossRefPubMedPubMedCentral

18.

Zarzour JG, Lockhart ME, West J, et al. (2017) Contrast-enhanced ultrasound classification of previously indeterminate renal lesions. J Ultrasound Med . https://doi.org/10.1002/jum.14208 PubMed

19.

Averkiou M, Powers J, Skyba D, Bruce M, Jensen S (2003) Ultrasound contrast imaging research. Ultrasound Q 19(1):27–37CrossRefPubMed

20.

de Jong N, Bouakaz A, Frinking P (2002) Basic acoustic properties of microbubbles. Echocardiography 19(3):229–240CrossRefPubMed

21.

Chiorean L, Caraiani C, Radzina M, et al. (2015) Vascular phases in imaging and their role in focal liver lesions assessment. Clin Hemorheol Microcirc 62(4):299–326. https://doi.org/10.3233/CH-151971 CrossRefPubMed

22.

D’Onofrio M, Crosara S, De Robertis R, Canestrini S, Mucelli RP (2015) Contrast-enhanced ultrasound of focal liver lesions. AJR Am J Roentgenol 205(1):W56–W66. https://doi.org/10.2214/AJR.14.14203 CrossRefPubMed

23.

Trillaud H, Bruel JM, Valette PJ, et al. (2009) Characterization of focal liver lesions with SonoVue-enhanced sonography: international multicenter-study in comparison to CT and MRI. World J Gastroenterol 15(30):3748–3756CrossRefPubMedPubMedCentral

24.

Wilson SR, Kim TK, Jang HJ, Burns PN (2007) Enhancement patterns of focal liver masses: discordance between contrast-enhanced sonography and contrast-enhanced CT and MRI. AJR Am J Roentgenol 189(1):W7–W12. https://doi.org/10.2214/AJR.06.1060 CrossRefPubMed

25.

Barreiros AP, Piscaglia F, Dietrich CF (2012) Contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma (HCC): comments on AASLD guidelines. J Hepatol 57(4):930–932. https://doi.org/10.1016/j.jhep.2012.04.018 CrossRefPubMed

26.

Furlan A, Marin D, Cabassa P, et al. (2012) Enhancement pattern of small hepatocellular carcinoma (HCC) at contrast-enhanced US (CEUS), MDCT, and MRI: intermodality agreement and comparison of diagnostic sensitivity between 2005 and 2010 American Association for the Study of Liver Diseases (AASLD) guidelines. Eur J Radiol 81(9):2099–2105. https://doi.org/10.1016/j.ejrad.2011.07.010 CrossRefPubMed

27.

Hanna RF, Miloushev VZ, Tang A, et al. (2016) Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol 41(1):71–90 ((NY)). https://doi.org/10.1007/s00261-015-0592-8 CrossRef

28.

Jang HJ, Kim TK, Burns PN, Wilson SR (2015) CEUS: an essential component in a multimodality approach to small nodules in patients at high-risk for hepatocellular carcinoma. Eur J Radiol 84(9):1623–1635. https://doi.org/10.1016/j.ejrad.2015.05.020 CrossRefPubMed

29.

Loria F, Loria G, Basile S, et al. (2016) Role of contrast-enhanced ultrasound in the evaluation of vascularization of hepatocellular carcinoma. Hepatoma Research . https://doi.org/10.20517/2394-5079.2016.27

30.

Mitchell DG, Bruix J, Sherman M, Sirlin CB (2015) LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology 61(3):1056–1065. https://doi.org/10.1002/hep.27304 CrossRefPubMed

31.

Nicolau C, Catala V, Vilana R, et al. (2004) Evaluation of hepatocellular carcinoma using SonoVue, a second generation ultrasound contrast agent: correlation with cellular differentiation. Eur Radiol 14(6):1092–1099. https://doi.org/10.1007/s00330-004-2298-0 CrossRefPubMed

32.

Rajesh S, Mukund A, Arora A, Jain D, Sarin SK (2013) Contrast-enhanced US-guided radiofrequency ablation of hepatocellular carcinoma. J Vasc Interv Radiol 24(8):1235–1240. https://doi.org/10.1016/j.jvir.2013.04.013 CrossRefPubMed

33.

Sangiovanni A, Manini MA, Iavarone M, et al. (2010) The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 59(5):638–644. https://doi.org/10.1136/gut.2009.187286 CrossRefPubMed

34.

Chen LD, Xu HX, Xie XY, et al. (2008) Enhancement patterns of intrahepatic cholangiocarcinoma: comparison between contrast-enhanced ultrasound and contrast-enhanced CT. Br J Radiol 81(971):881–889. https://doi.org/10.1259/bjr/22318475 CrossRefPubMed

35.

Chen LD, Xu HX, Xie XY, et al. (2010) Intrahepatic cholangiocarcinoma and hepatocellular carcinoma: differential diagnosis with contrast-enhanced ultrasound. Eur Radiol 20(3):743–753. https://doi.org/10.1007/s00330-009-1599-8 CrossRefPubMed

36.

D’Onofrio M, Vecchiato F, Cantisani V, et al. (2008) Intrahepatic peripheral cholangiocarcinoma (IPCC): comparison between perfusion ultrasound and CT imaging. Radiol Med 113(1):76–86. https://doi.org/10.1007/s11547-008-0225-1 CrossRefPubMed

37.

Galassi M, Iavarone M, Rossi S, et al. (2013) Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. Liver Int 33(5):771–779. https://doi.org/10.1111/liv.12124 CrossRefPubMed

38.

Han J, Liu Y, Han F, et al. (2015) The degree of contrast washout on contrast-enhanced ultrasound in distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma. Ultrasound Med Biol 41(12):3088–3095. https://doi.org/10.1016/j.ultrasmedbio.2015.08.001 CrossRefPubMed

39.

Kong WT, Wang WP, Zhang WW, et al. (2014) Contribution of contrast-enhanced sonography in the detection of intrahepatic cholangiocarcinoma. J Ultrasound Med 33(2):215–220. https://doi.org/10.7863/ultra.33.2.215 CrossRefPubMed

40.

Li R, Yuan MX, Ma KS, et al. (2014) Detailed analysis of temporal features on contrast enhanced ultrasound may help differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma in cirrhosis. PLoS ONE 9(5):e98612. https://doi.org/10.1371/journal.pone.0098612 CrossRefPubMedPubMedCentral

41.

Lu Q, Xue LY, Wang WP, Huang BJ, Li CX (2015) Dynamic enhancement pattern of intrahepatic cholangiocarcinoma on contrast-enhanced ultrasound: the correlation with cirrhosis and tumor size. Abdom Imaging 40(6):1558–1566. https://doi.org/10.1007/s00261-015-0379-y CrossRefPubMed

42.

Wildner D, Bernatik T, Greis C, et al. (2015) CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients—early or late washout matters: a subanalysis of the DEGUM multicenter trial. Ultraschall Med 36(2):132–139. https://doi.org/10.1055/s-0034-1399147 CrossRefPubMed

43.

Wildner D, Pfeifer L, Goertz RS, et al. (2014) Dynamic contrast-enhanced ultrasound (DCE-US) for the characterization of hepatocellular carcinoma and cholangiocellular carcinoma. Ultraschall Med 35(6):522–527. https://doi.org/10.1055/s-0034-1385170 CrossRefPubMed

44.

Xu HX, Chen LD, Liu LN, et al. (2012) Contrast-enhanced ultrasound of intrahepatic cholangiocarcinoma: correlation with pathological examination. Br J Radiol 85(1016):1029–1037. https://doi.org/10.1259/bjr/21653786 CrossRefPubMedPubMedCentral

45.

Yuan MX, Li R, Zhang XH, et al. (2016) Factors affecting the enhancement patterns of intrahepatic cholangiocarcinoma (ICC) on contrast-enhanced ultrasound (CEUS) and their pathological correlations in patients with a single lesion. Ultraschall Med 37(6):609–618. https://doi.org/10.1055/s-0034-1399485 PubMed

46.

Barr RG (2017) Is there a need to modify the Bosniak renal mass classification with the addition of contrast-enhanced sonography? J Ultrasound Med 36(5):865–868. https://doi.org/10.7863/ultra.16.06058 CrossRefPubMed

47.

Malhi H, Grant EG, Duddalwar V (2014) Contrast-enhanced ultrasound of the liver and kidney. Radiol Clin N Am 52(6):1177–1190. https://doi.org/10.1016/j.rcl.2014.07.005 CrossRefPubMed

48.

Schneider A, Johnson L, Goodwin M, Schelleman A, Bellomo R (2011) Bench-to-bedside review: contrast enhanced ultrasonography—a promising technique to assess renal perfusion in the ICU. Crit Care 15(3):157. https://doi.org/10.1186/cc10058 CrossRefPubMedPubMedCentral

49.

Lv F, Ning Y, Zhou X, et al. (2014) Effectiveness of contrast-enhanced ultrasound in the classification and emergency management of abdominal trauma. Eur Radiol 24(10):2640–2648. https://doi.org/10.1007/s00330-014-3232-8 CrossRefPubMed

50.

Westwood M, Joore M, Grutters J, et al. (2013) Contrast-enhanced ultrasound using SonoVue(R) (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis. Health Technol Assess 17(16):1–243. https://doi.org/10.3310/hta17160 CrossRef

51.

Smajerova M, Petrasova H, Little J, et al. (2016) Contrast-enhanced ultrasonography in the evaluation of incidental focal liver lesions: a cost-effectiveness analysis. World J Gastroenterol 22(38):8605–8614. https://doi.org/10.3748/wjg.v22.i38.8605 CrossRefPubMedPubMedCentral

52.

Chung YE, Kim KW (2015) Contrast-enhanced ultrasonography: advance and current status in abdominal imaging. Ultrasonography 34(1):3–18. https://doi.org/10.14366/usg.14034 CrossRefPubMed

Title: Practical advantages of contrast-enhanced ultrasound in abdominopelvic radiology
Authors: Praveen Ganti Ranganath
Michelle L. Robbin
Susan J. Back
Edward G. Grant
David T. Fetzer
Publication date: 01-04-2018
Publisher: Springer US
Published in: Abdominal Radiology / Issue 4/2018
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-017-1442-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2018

Hypervascular pancreatic “lesions”: a pattern-based approach to differentiation

Imaging with ultrasound contrast agents: current status and future

Machine learning for medical ultrasound: status, methods, and future opportunities

Contrast-enhanced ultrasound (CEUS) of the abdominal vasculature

Applications of contrast-enhanced ultrasound in the kidney

Artifacts in contrast-enhanced ultrasound: a pictorial essay

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage